World War III: Boeing offices in Kyiv damaged by Russian airstrike, is Moscow expanding the war to US interests?
World War III: Russia air attack damages Boeing building in Ukraine, raises US security concerns-
Russia launched one of its largest air assaults yet on Ukraine between June 9 and 10, 2025—damaging a building used by Boeing's engineering and technical teams in Kyiv, according to reports from the
Financial Times
and
Reuters
. While none of the company's staff were harmed, the strike is raising urgent questions: Is Moscow now targeting American corporate interests as part of its war strategy?
The attack was part of a massive offensive involving over 315 drones and multiple missiles, hitting multiple Ukrainian cities, including Kyiv and Odesa. Boeing, which has had a long-standing presence in Ukraine and employs more than 1,000 local workers, confirmed that its operations remain unaffected. However, Ukrainian officials and Western observers view the targeting of Boeing as a deliberate signal aimed at both Kyiv and Washington.
Is Russia deliberately targeting American-linked operations?
A calculated strike on US defense support
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
0:00
Loaded
:
0%
0:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
default
, selected
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Minturno: Volare a Dubai con un jet privato, i costi spiegati
Volare a Dubai con un jet privato | Ricerca annunci
Scopri di più
Boeing isn't just another foreign company in Ukraine. It's a pillar of US aerospace and defense, closely tied to military logistics and equipment. Ukrainian authorities say the strike was part of a growing Russian campaign aimed at weakening Western-backed defense infrastructure—especially those helping Ukraine stay in the fight.
Escalation in Russia's aerial tactics
The strike came amid a wave of intensified attacks from Russia. Along with Kyiv, cities like Odesa were hit hard, including tragic strikes on civilian targets like a maternity hospital. The scale and coordination of the June assault signal
a new phase in Moscow's military posture
.
Live Events
A warning shot to Washington?
By hitting Boeing—a key US defense contractor—Russia may be trying to raise the stakes, betting that it can
pressure American politics or sow division
among NATO allies. However, instead of retreating, US-aligned entities in Ukraine may double down, interpreting the attack as
a call for deeper engagement
, not withdrawal.
Why did Russia target Boeing's facility in Kyiv?
The airstrike on Boeing's office in Kyiv appears to have been part of a wider military campaign that included 315 drones, two ballistic missiles, and five cruise missiles targeting cities across Ukraine — including Kyiv and Odesa. This wave of attacks came after Ukraine's own drone strike earlier this month hit deep into Russian territory, damaging bomber aircraft near the Arctic Circle.
Although Boeing has not confirmed if it was deliberately targeted, the scale and precision of the strike — and the building's prominence — have raised serious questions about Russia's intentions. Boeing's operations in Ukraine focus on engineering and technical support and include a close relationship with Ukrainian aircraft manufacturer Antonov, known for producing large transport aircraft.
What was the extent of damage and impact on Boeing's operations?
Despite the visible damage to its Kyiv facility, Boeing has reported no disruption to its operations in Ukraine. Andriy Koryagin, deputy general director of Boeing's Ukraine operation, said business continues as normal. The company has even been actively hiring, with a job posting dated June 2 seeking an interior design and certification engineering manager.
Boeing employs over 1,000 people across Ukraine, and according to the ACC's president Andy Hunder, it has remained resilient throughout more than three years of conflict. Boeing did not comment in detail on the strike but emphasized its focus on employee safety and praised its staff's strength during ongoing challenges.
Could this be part of a broader Russian strategy against US companies?
This attack on Boeing fits a concerning pattern. Russia has repeatedly struck industrial sites, power stations, and military-related facilities across Ukraine. Ukrainian Foreign Minister Andriy Sybiha told the
FT
that such strikes reflect 'Putin's disregard for US peace efforts' and show why US support remains critical.
Beyond Boeing, Russia has also previously damaged or seized other major US-owned assets. In early 2022, a Coca-Cola facility near Kyiv was occupied and destroyed. Russian troops there reportedly found and drank Jack Daniel's whiskey, which, humorously but tellingly, slowed their advancement. In 2014, during the earlier conflict, Russian forces seized a Cargill agricultural facility, and another one was later lost in Kakhovka.
According to Hunder, 32% of ACC's nearly 700 member companies have lost employees to Russian attacks, and nearly half have suffered facility damage, from shattered windows to complete destruction.
What does this mean for Boeing's defense cooperation with Ukraine?
The Boeing-Antonov partnership has grown significantly over the past year. In 2024, both companies signed a memorandum of understanding focused on defense projects. During the Munich Security Conference in February 2025, Boeing's defense executives met with Ukrainian Defense Minister Rustem Umerov to discuss joint ventures, particularly around ammunition and aerial strike systems.
According to Ukraine's Defense Ministry, the two parties explored joint production of unmanned aerial systems, which may now put Boeing more squarely in Russia's crosshairs. While Boeing's primary role in Ukraine has been technical and engineering-based, its expanding defense connections make it a more visible player in the broader war effort.
Is Russia escalating attacks on foreign companies aiding Ukraine?
Western intelligence and research bodies — including the Center for Strategic and International Studies (CSIS) — have been tracking a steady rise in Russian sabotage and subversion targeting Western businesses. Many of these firms are involved in military support, weapons production, and logistics for Ukraine.
The Boeing strike could signal a broader Russian strategy to intimidate or weaken Western corporate engagement in Ukraine's defense and recovery sectors. With peace talks stalled and President Vladimir Putin holding firm on his demands, the risk to foreign firms operating in Ukraine may only grow.
What's next for US involvement as Russia targets American firms?
President Donald Trump has expressed growing frustration with Russia's continued aggression. The attack on Boeing — a global symbol of American aerospace power — may further test his administration's stance on Ukraine. Ukrainian leaders, including Foreign Minister Sybiha, have urged stronger US engagement, not just in diplomacy but also in Ukraine's security infrastructure.
As the war enters a new and more unpredictable phase, the line between civilian operations and military targets continues to blur — especially when American companies like Boeing are seen as key contributors to Ukraine's defense capacity.
FAQs:
Q1. Why did Russia target the Boeing building in Ukraine?
Russia likely targeted Boeing due to its defense work with Ukraine's Antonov aircraft maker.
Q2. Is Boeing still operating in Ukraine after the attack?
Yes, Boeing continues operations and hiring in Ukraine despite the Kyiv building damage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
27 minutes ago
- Indian Express
G7 leaders struggle for unity as Trump says removing Russia from group was a mistake
Group of Seven leaders met on Monday seeking a common approach on wars in Ukraine and the Middle East but before their summit formally began, US President Donald Trump said removing Russia from the former Group of Eight over a decade ago had been a mistake. Trump's overt statement of support for Russian President Vladimir Putin was an early challenge for a once tight-knit grouping that has struggled to find unity as Washington retreats from multilateralism. G7 leaders from Britain, Canada, France, Germany, Italy, Japan, and the US, along with the European Union, are convening in the resort area of Kananaskis in the Canadian Rockies until Tuesday. Speaking alongside Canadian Prime Minister Mark Carney, Trump said the former Group of Eight had been wrong to kick out Russia in 2014 after it annexed Crimea. 'This was a big mistake,' Trump said, adding he believed Russia would not have invaded Ukraine in 2022 had Putin not been ejected. 'Putin speaks to me. He doesn't speak to anybody else … he's not a happy person about it. I can tell you that he basically doesn't even speak to the people that threw him out, and I agree with him,' Trump said. His comments raise doubts about how much Ukrainian President Volodymyr Zelenskyy can achieve when he meets the leaders on Tuesday. European nations say they want to persuade Trump to back tougher sanctions on Moscow. Zelenskyy said he planned to discuss new weapons purchases for Ukraine with Trump. Trump spoke on Saturday with Putin and suggested the Russian leader could play a mediation role between Israel and Iran. French President Emmanuel Macron dismissed the idea, arguing that Moscow could not be a negotiator because it had started an illegal war against Ukraine. A European diplomat said Trump's suggestion showed that Russia was very much on U.S. minds. European officials said they hoped to use Tuesday's meeting with Zelenskyy and NATO Secretary General Mark Rutte and next week's NATO summit to convince Trump to toughen his stance. 'The G7 should have the objective for us to converge again, for Ukraine to get a ceasefire to lead to a robust and lasting peace, and in my view it's a question of seeing whether President Trump is ready to put forward much tougher sanctions on Russia,' Macron said. With an escalating Israel-Iran conflict, the summit in Canada is seen as a vital moment to try to restore a semblance of unity among democratic powerhouses. In another early sign the group may struggle to reach agreement on key issues, a US official said Trump would not sign a draft statement calling for de-escalation of the Israel-Iran conflict. A Canadian official, though, said the conflict would come up in bilateral meetings throughout the day and it was too early to speculate on the outcome of those conversations. A senior European diplomat echoed those comments, saying Trump had yet to make a decision. Canada has abandoned any effort to adopt a comprehensive communique to avert a repeat of the 2018 summit in Quebec, when Trump instructed the US delegation to withdraw its approval of the final communique after leaving. Leaders have prepared several draft documents seen by Reuters, including on migration, artificial intelligence, and critical mineral supply chains. None of them have been approved by the United States, however, according to sources briefed on the documents. Europeans are on the same page on most issues, a European diplomat said. But without Trump, it is unclear if there will be any declarations, the diplomat said. The first five months of Trump's second term upended foreign policy on Ukraine, raised anxiety over his closer ties to Russia, and resulted in tariffs on US allies. Talks on Monday will centre around the economy, advancing trade deals, and China. Efforts to reach an agreement to lower the G7 price cap on Russian oil, even if Trump decided to opt out, were complicated by a temporary surge in oil prices since Israel launched strikes on Iran on June 12, two diplomatic sources said. Oil prices fell on Monday on reports Iran was seeking a truce. The escalation between the two regional foes is high on the agenda, with diplomatic sources saying they hope to urge restraint and a return to diplomacy and would encourage Trump to sign a declaration. 'I do think there's a consensus for de-escalation. Obviously, what we need to do today is to bring that together and to be clear about how it is to be brought about,' British Prime Minister Keir Starmer told reporters.
Time of India
28 minutes ago
- Time of India
Fintech Aspora raises $53 million to expand cross-border banking for global Indians
Bengaluru: Aspora, a London-headquartered fintech startup focused on providing banking services for immigrant communities, has raised $53 million co-led by Sequoia and Greylock, with participation from Quantum Light Ventures. The company, which was previously known as Vance, is targeting the global Indian diaspora as its first major customer base. The latest round follows Aspora's $35 million and a $5 million seed extension last year. Over the past six months, the company has raised a total of $93 million across multiple funding rounds. Founded by Parth Garg in 2022, who dropped out of Stanford University to start the venture, Aspora is building cross-border financial products for non-resident Indians (NRIs) and other diaspora segments. According to the company, it currently serves 250,000 users, with its primary user base in the UAE. Over the past six months, Aspora's transaction volume has grown from $400 million to more than $2 billion, with users saving over $15 million in fees compared to traditional providers. Aspora offers zero-fee remittance transfers from the UAE and provides exchange rates identical to market benchmarks displayed on Google, while fees may apply in other markets. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo The company currently operates across the UK, EU, and UAE, and plans to launch in the United States in July 2025, followed by expansion into Canada, Australia, and Singapore by the end of the year. In addition to institutional investors, Aspora is backed by a group of individual investors that includes Balaji Srinivasan (former CTO, Coinbase), Sundeep Jain (former CPO, Uber), Prasanna Sankar (co-founder, Rippling), and Chad West (former global marketing head, Revolut).
Time of India
30 minutes ago
- Time of India
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads ( Originally published on Jun 16, 2025 ) U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters."They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData.A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%."I think it's only accelerating," Gleason Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs."The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals.'WAKEUP CALL'By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say.U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week."We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time."Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry."It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
